US Food Regulator Made 9 Observations Post Halol Unit Inspection: Sun Pharma
New Delhi: Drug major Sun Pharmaceutical Industries today said that the US health regulator made nine observations after the completion of inspection of its Halol facility in Gujarat.
The United States Food and Drug Administration (USFDA) inspected the Halol facility from November 17, 2016 through December 1, 2016, Sun Pharma said in a BSE filing.
"At the conclusion of the inspection, the USFDA issued a Form-483, citing nine inspectional observations. None of those observations were characterised by the USFDA as repeat observations," it added.However, the company did not disclose the observations made by the USFDA.
The company is preparing responses to the observations, which will be submitted to USFDA within 15 business days of receipt of the Form-483, Sun Pharma said.
"The company intends to implement promptly any corrective actions and improvements that may be necessary as a result of the observations and to continue to work cooperatively with USFDA," Sun Pharma said.
Sun Pharma was earlier issued a warning letter by the USFDA for its Halol facility in December 2015. The letter followed inspection of the facility in September 2014 by FDA inspectors. The company has been making efforts to make the Halol plant CGMP-compliant again.
As per the USFDA, observations are made in Form 483 when investigators feel that conditions or practices in the facility are such that products may become adulterated or render injuries to health. The FDA Form 483 notifies the company's management of objectionable conditions.
Shares of Sun Pharmaceutical Industries were today trading at Rs 675.85 per scrip in the afternoon trade on BSE, up 1.79 per cent from its previous close.
Â
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
